Carnosine / NO Cancer Research Results

Carno, Carnosine: Click to Expand ⟱
Features:

Carnosine (CAR; β-alanyl-L-histidine) is an endogenous dipeptide and dietary supplement (high in meat; also synthesized).
Primary mechanisms (conceptual rank):
1) Carbonyl/aldehyde scavenging + anti-glycation (AGE) suppression → proteostasis stress ↓ (P/R)
2) Cancer metabolism interference (Warburg/glycolysis pressure) → proliferation ↓ (model-dependent; often high concentration) (R/G)
3) Metal chelation + ROS/RNS buffering (secondary redox modulation) (P/R; context-dependent)
Bioavailability / PK: Orally absorbed, but rapidly hydrolyzed in human blood by carnosinase (CN1) → very short circulating half-life; sustained systemic CAR exposure is limited vs β-alanine/histidine metabolites.
In-vitro vs realistic exposure: Many anti-proliferative / glycolysis effects are reported at high µM–mM CAR in vitro, commonly exceeding realistic systemic CAR exposure due to rapid serum hydrolysis.
Clinical evidence status (cancer): Predominantly preclinical for direct anti-cancer effects; human oncology evidence is mainly adjunct/supportive (e.g., zinc-L-carnosine for radiation-related symptoms), not established as an anti-tumor monotherapy.

L-Carnosine (usually just called "Carnosine") is a naturally occurring dipeptide composed of L-histidine and β-alanine, found in high concentrations in muscle and brain tissue.
-Source: only found in animals Beef(372mg/100g), ChickenBreast(290mg/100g), Pork(276mg/100g), TurkeyBreast(240mg/100g)
-Anserine is a derivative of carnosine
-Scavenges reactive oxygen species (ROS)
-Inhibits formation of AGEs (advanced glycation end-products), which are linked to aging and neurodegeneration.
-Metal chelator: Binds excess zinc, copper, and iron—important in brain health.


Carnosine (CAR) — Pathway / Axis Effects (Cancer vs Normal)

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 Carbonyl stress / anti-glycation (AGE) ↓ proteotoxic/carbonyl stress (context-dependent) ↓ glycation damage (protective) P/R Cell stress buffering Core “chemoprotective” chemistry: nucleophilic scavenging of reactive carbonyls; cancer-direction depends on whether tumor relies on carbonyl-stress adaptation.
2 Warburg / glycolysis pressure ↓ glycolysis flux (model-dependent; high concentration only) ↔ R/G Anti-proliferative (subset) Frequently reported in vitro with supraphysiologic CAR; translation constrained by rapid serum hydrolysis in humans.
3 Mitochondrial function / energetic stress ↔ / ↑ energetic stress (model-dependent) ↔ / protective (context-dependent) R Growth suppression vs resilience Direction varies by baseline metabolic state and substrate availability; often secondary to carbonyl/redox effects.
4 ROS ↓ ROS (secondary; context-dependent) ↓ oxidative damage (protective) P/R Redox buffering Typically described as antioxidant buffering; paradoxical “ROS ↑” cytotoxicity is not a dominant CAR narrative.
5 NRF2 (stress-response axis) ↔ / ↑ cytoprotection (context-dependent; resistance risk) ↔ / ↑ protective G Adaptive stress signaling If NRF2 is already oncogenic (e.g., KEAP1/NFE2L2-altered tumors), further cytoprotection could be undesirable.
6 Ca²⁺ (ER/mitochondria stress coupling) ↔ (not primary; model-dependent) ↔ R Stress modulation (secondary) Include only as a secondary axis: CAR’s dominant reported levers are carbonyl/redox/metabolic rather than direct Ca²⁺ channel control.
7 Ferroptosis ↔ (context-dependent) ↔ R/G Unclear / secondary CAR’s anti-lipid-peroxidation tendency could oppose ferroptosis in some contexts; evidence is not central vs carbonyl/AGE chemistry.
8 Clinical Translation Constraint Human systemic CAR exposure is constrained by rapid serum hydrolysis (CN1); much in-vitro anti-cancer work uses high µM–mM. Strongest human oncology signal is adjunct/supportive use (e.g., zinc-L-carnosine symptom prevention), not proven tumor regression. — PK-limited; adjunct-only Consider delivery strategies/analogs (e.g., carnosinase-resistant histidine dipeptides) if pursuing systemic pharmacology.

TSF legend: P: 0–30 min (primary/rapid effects; direct enzyme/redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes)
NO, Nitric Oxide: Click to Expand ⟱
Source:
Type:
Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells.
The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment.
Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS).

– In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer.

• Expression Patterns in Tumors:
– Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment.

– Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation.
Scientific Papers found: Click to Expand⟱
3871- Carno,    Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper
- Review, NA, NA
*ROS↓, *NO↓, *Inflam↓,
3872- Carno,    Carnosine Protects Macrophages against the Toxicity of Aβ1-42 Oligomers by Decreasing Oxidative Stress
- in-vitro, AD, NA
*antiOx↑, *Inflam↓, *Aβ↓, *neuroP↑, *ROS↓, *NO↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ROS↓, 2,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 2,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: NO, Nitric Oxide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:351  Target#:563  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page